New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:15 EDTACST, NEPTNeptune Technologies, Acasti Pharma, NeuroBio announce resignation of CEO
Neptune Technologies & Bioressources (NEPT), Acasti Pharma (ACST) and NeuroBioPharm jointly announce the resignation of Henri Harland as president and CEO of Neptune, Acasti and NeuroBio with immediate effect. Harland remains a director of Neptune, Acasti and NeuroBio. The businesses will continue to be managed by a management and operations committee under the leadership of Neptune's CFO, André Godin. The search for a new president and CEO will commence immediately.
News For NEPT;ACST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:08 EDTNEPTNeptune Technologies appoints Jim Hamilton as CEO
Subscribe for More Information
November 11, 2014
08:11 EDTACSTAcasti Pharma receives NASDAQ notification regarding minimum bid requirements
Acasti Pharma announces that on November 7 it received notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum bid price of $1.00 per share for the last 30 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2) – bid price. The NASDAQ notification has no immediate effect on the listing of the Corporation's shares. Under NASDAQ rule 5810(c)(3)(A) – compliance period, the corporation has 180 calendar days, or until May 6, 2015, to regain compliance. If at any time over this period the bid price of Acasti's shares closes at $1.00 per share or more for a minimum of ten consecutive business days, NASDAQ will provide written confirmation of compliance and the matter will be closed. If Acasti does not regain compliance within the initial 180-day period, but meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for the NASDAQ Capital Market, except for the bid price requirement, the corporation may be eligible for an additional 180 calendar days to regain compliance. If the corporation is not granted additional time, then the securities will be subject to delisting, at which time the corporation may appeal the delisting determination to a NASDAQ Hearings Panel. The company intends to evaluate all available options to resolve the deficiency and regain compliance with the Minimum Bid Price Rule.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use